GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (OTCPK:ENZN) » Definitions » Shiller PE Ratio

Enzon Pharmaceuticals (Enzon Pharmaceuticals) Shiller PE Ratio : 0.46 (As of Apr. 25, 2024)


View and export this data going back to 1984. Start your Free Trial

What is Enzon Pharmaceuticals Shiller PE Ratio?

As of today (2024-04-25), Enzon Pharmaceuticals's current share price is $0.07797. Enzon Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $0.17. Enzon Pharmaceuticals's Shiller PE Ratio for today is 0.46.

The historical rank and industry rank for Enzon Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

ENZN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 0.35   Med: 0.8   Max: 7.27
Current: 0.46

During the past years, Enzon Pharmaceuticals's highest Shiller PE Ratio was 7.27. The lowest was 0.35. And the median was 0.80.

ENZN's Shiller PE Ratio is ranked better than
97.95% of 146 companies
in the Biotechnology industry
Industry Median: 33.335 vs ENZN: 0.46

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Enzon Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.011. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.17 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Enzon Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Enzon Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzon Pharmaceuticals Shiller PE Ratio Chart

Enzon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.85 1.78 1.16 0.56

Enzon Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 1.24 1.01 0.81 0.56

Competitive Comparison of Enzon Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Enzon Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzon Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Enzon Pharmaceuticals's Shiller PE Ratio falls into.



Enzon Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Enzon Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=0.07797/0.17
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzon Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Enzon Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.011/129.4194*129.4194
=0.011

Current CPI (Dec. 2023) = 129.4194.

Enzon Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.190 99.695 0.247
201406 0.160 100.560 0.206
201409 0.170 100.428 0.219
201412 0.130 99.070 0.170
201503 0.160 99.621 0.208
201506 0.090 100.684 0.116
201509 -0.040 100.392 -0.052
201512 0.280 99.792 0.363
201603 0.030 100.470 0.039
201606 0.020 101.688 0.025
201609 0.020 101.861 0.025
201612 -0.110 101.863 -0.140
201703 0.010 102.862 0.013
201706 0.090 103.349 0.113
201709 0.003 104.136 0.004
201712 0.010 104.011 0.012
201803 -0.010 105.290 -0.012
201806 -0.010 106.317 -0.012
201809 -0.010 106.507 -0.012
201812 0.150 105.998 0.183
201903 -0.010 107.251 -0.012
201906 0.000 108.070 0.000
201909 -0.010 108.329 -0.012
201912 0.000 108.420 0.000
202003 -0.010 108.902 -0.012
202006 -0.010 108.767 -0.012
202009 -0.010 109.815 -0.012
202012 -0.010 109.897 -0.012
202103 -0.010 111.754 -0.012
202106 -0.010 114.631 -0.011
202109 -0.010 115.734 -0.011
202112 -0.010 117.630 -0.011
202203 -0.011 121.301 -0.012
202206 -0.010 125.017 -0.010
202209 -0.010 125.227 -0.010
202212 0.010 125.222 0.010
202303 -0.005 127.348 -0.005
202306 -0.005 128.729 -0.005
202309 -0.003 129.860 -0.003
202312 0.011 129.419 0.011

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Enzon Pharmaceuticals  (OTCPK:ENZN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Enzon Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzon Pharmaceuticals (Enzon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company earns revenue in the form of royalties. Primary source of royalty revenues derived from the sales of PegIntron, which is marketed by Merck.
Executives
Randolph C Read director C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022
Jaffrey Adam Firestone director C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479
Family Fund Couchman other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jordan Bleznick director C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016
Pearce Michael Cooper other: See explanation of responses 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Harper Asset Management Llc other: See explanation of responses 2945 S CENTER GREEN CT, G215, BOULDER CO 80301
Brian James Harper other: See explanation of responses 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301
Myrexis, Inc. other: See Footnote 1 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020
Xstelos Corp. other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jonathan Couchman 10 percent owner, other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Carl C Icahn 10 percent owner C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160
Richard L Feinstein officer: VP-Finance and PFO
Jonathan Christodoro director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Jennifer Isacoff Mcnealey director C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121

Enzon Pharmaceuticals (Enzon Pharmaceuticals) Headlines